Anixa Biosciences, Inc.ANIXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank8
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P8
Near historical low
vs 5Y Ago
-6.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q1 2026-107.97%
Q4 202516.94%
Q3 2025-0.53%
Q2 202548.24%
Q1 2025-213.27%
Q4 202464.93%
Q3 20240.00%
Q2 2024-14.47%
Q1 2024-17.27%
Q4 2023-36.26%
Q3 2023-79.06%
Q2 202359.41%
Q1 2023-24.80%
Q4 2022-14.11%
Q3 202239.46%
Q2 2022-92.65%
Q1 2022-14.64%
Q4 202129.50%
Q3 2021-19.24%
Q2 2021-6.15%
Q1 202117.26%
Q4 2020-9.54%
Q3 202017.05%
Q2 202018.71%
Q1 2020-43.18%
Q4 2019-108.88%
Q3 201955.39%
Q2 2019-7.91%
Q1 2019-30.23%
Q4 201812.74%
Q3 2018-57.57%
Q2 201844.59%
Q1 2018-81.25%
Q4 201740.91%
Q3 2017-16.24%
Q2 2017-47.46%
Q1 2017-6.87%
Q4 201616.16%
Q3 201639.73%
Q2 2016-153.89%